Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics

Akebia Therapeutics, Inc.

2025-Q2 EPS reported $0.02 revenue$119,808,000

Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.
Vafseo net product revenue $13.3M; prescription demand grew ~55% QoQ; >725 prescribers.
DaVita begins operational pilot in August at 100+ clinics; DCI/IRC protocols by Sept.
Auryxia net revenue $47.2M, up from $41.2M; no ANDA approved despite LOE in March.
Cash $137.3M; company believes financed to profitability.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.